Grigory A. Somsikov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Grigory A. Somsikov has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Alexander E. Zhigulin
Children’s State Clinical Hospital of St. Vladimir of Moscow City Health Department, Moscow 107014, Russia
1 shared publication - Daria M. Guseva
Research Centre for Medical Genetics, Moscow 115522, Russia
1 shared publication - Ekaterina V. Bychkova
Research Centre for Medical Genetics, Moscow 115522, Russia
1 shared publication - Garik B. Sagoyan
N.N. Blokhin National Medical Research Center of Oncology of Ministry of Health of the Russian Federation
1 shared publication - Ilya A. Volodin
Research Centre for Medical Genetics, 115522 Moscow, Russia
1 shared publication - Nataliya A. Semenova
Research Centre for Medical Genetics, 115522 Moscow, Russia
1 shared publication
Latest Publications
- Open Access
- 12 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (22) , 10127
Diagnostic Yield and Variant Spectrum in 375 Patients with Segmental Overgrowth and Vascular Malformations: Implications for Panel Design and Molecular Testing Strategies
Segmental overgrowth and vascular malformations comprise a group of diseases caused by postzygotic variants in genes that regulate cell growth, proliferation, and angiogenesis. The best-characterized group is the PIK3CA-related overgrowth spectrum (PROS), which includes syndromes sharing variants in the PIK3CA gene. Beyond PIK3CA, the genes involved fall into two mechanistically distinct groups, with gain-of-function (GNAQ, GNA11, TEK, AKT1, AKT3, MTOR, PIK3R1) and loss-of-function (RASA1, GLMN, PTEN) causative variants. What remains poorly established is how effectively a molecular diagnosis is actually achieved in routine practice, and how this depends on the referral clinical diagnosis. By targeted panel deep sequencing in patients with segmental overgrowth and/or a vascular malformation, we have identified at least one pathogenic / likely pathogenic (P/LP) genetic variant in 266 of the 375 successfully tested patients, giving an overall diagnostic yield of 70.9%. The yield was 63.5% in patients with isolated overgrowth (94 of 148), 75.0% in patients with an isolated vascular malformation (111 of 148) and 77.2% in patients with a combined or syndromic phenotype (61 of 79). The 277 P/LP variants identified were distributed across 17 genes; PIK3CA accounted for 141 variants (50.9%), GNAQ for 44 (15.9%), TEK for 31 (11.2%), RASA1 for 15 (5.4%) and GNA11 for 11 (4.0%); these five genes together accounted for 87.4% of the variants. The spectrum was highly concentrated: the ten most frequent variants accounted for 57.0% of the P/LP variants, with GNAQ variant p.Arg183Gln (15.2%) and PIK3CA hotspot variants p.Glu542Lys (8.7%), p.Glu545Lys (6.9%), and p.His1047Arg (7.6%). In several genes, variants were restricted to specific regions: in GNAQ and GNA11 to two codons, 183 and 209 (98.2% of all findings), and in TEK to the 3′-terminus. Considered together with the referral diagnosis, the distribution of variants, their allele fractions and their mechanisms of pathogenicity suggest molecular testing strategies.
- 12 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (22) , 10127
Open AccessDiagnostic Yield and Variant Spectrum in 375 Patients with Segmental Overgrowth and Vascular Malformations: Implications for Panel Design and Molecular Testing Strategies
Segmental overgrowth and vascular malformations comprise a group of diseases caused by postzygotic variants in genes that regulate cell growth, proliferation, and angiogenesis. The best-characterized group is the PIK3CA-related overgrowth spectrum (PROS), which includes syndromes sharing variants in the PIK3CA gene. Beyond PIK3CA, the genes involved fall into two mechanistically distinct groups, with gain-of-function (GNAQ, GNA11, TEK, AKT1, AKT3, MTOR, PIK3R1) and loss-of-function (RASA1, GLMN, PTEN) causative variants. What remains poorly established is how effectively a molecular diagnosis is actually achieved in routine practice, and how this depends on the referral clinical diagnosis. By targeted panel deep sequencing in patients with segmental overgrowth and/or a vascular malformation, we have identified at least one pathogenic / likely pathogenic (P/LP) genetic variant in 266 of the 375 successfully tested patients, giving an overall diagnostic yield of 70.9%. The yield was 63.5% in patients with isolated overgrowth (94 of 148), 75.0% in patients with an isolated vascular malformation (111 of 148) and 77.2% in patients with a combined or syndromic phenotype (61 of 79). The 277 P/LP variants identified were distributed across 17 genes; PIK3CA accounted for 141 variants (50.9%), GNAQ for 44 (15.9%), TEK for 31 (11.2%), RASA1 for 15 (5.4%) and GNA11 for 11 (4.0%); these five genes together accounted for 87.4% of the variants. The spectrum was highly concentrated: the ten most frequent variants accounted for 57.0% of the P/LP variants, with GNAQ variant p.Arg183Gln (15.2%) and PIK3CA hotspot variants p.Glu542Lys (8.7%), p.Glu545Lys (6.9%), and p.His1047Arg (7.6%). In several genes, variants were restricted to specific regions: in GNAQ and GNA11 to two codons, 183 and 209 (98.2% of all findings), and in TEK to the 3′-terminus. Considered together with the referral diagnosis, the distribution of variants, their allele fractions and their mechanisms of pathogenicity suggest molecular testing strategies.